Inventiva stock price target raised to $13 from $9 at Guggenheim

Investing.com - Guggenheim raised its price target on Inventiva SA (NASDAQ:IVA) to $13.00 from $9.00 on Tuesday, while maintaining a Buy rating on the stock. The company, currently valued at $719 million, has seen its shares surge nearly 190% year-to-date, according to InvestingPro data.

The firm cited increased enthusiasm for the MASH (metabolic dysfunction-associated steatohepatitis) market and the target patient population at launch for the company’s lanifibranor (lani) treatment.

Guggenheim views lanifibranor as potentially the "next and best-in-class oral treatment" for MASH fibrosis patients and those with Type 2 diabetes, noting that Inventiva’s NATiV3 trial remains on track.

The research firm also highlighted Inventiva’s strengthened leadership team with the additions of Jason Campagna and Martine Zimmermann, along with ongoing preparation for regulatory filing.

Guggenheim expressed interest in Inventiva’s upcoming analyst day on October 8, where the firm hopes to learn more about lanifibranor’s global positioning strategy.

In other recent news, Inventiva has seen several significant developments. Piper Sandler initiated coverage on Inventiva with an Overweight rating, highlighting the potential of its lead asset, lanifibranor, which is in development for metabolic dysfunction-associated steatohepatitis (MASH). This comes ahead of Phase 3 NATiV3 topline results expected in the second half of 2026. Additionally, Inventiva announced leadership changes, appointing Jason Campagna as President of Research and Development and Chief Medical Officer, and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance. Campagna brings experience from his previous role as Chief Medical Officer at Q32 Bio. In another strategic move, Inventiva appointed Renée Aguiar-Lucander, former CEO of Calliditas, to its Board of Directors. These appointments follow shareholder approval at the company’s recent Annual General Meeting, as Inventiva continues to advance its drug candidate lanifibranor through late-stage clinical development.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.